What’s Next For Digital Therapeutics?

What if your prescription came with an app instead of a pill? In this episode of Healthcare in Action, Jon Lange speaks with Dr. Corey McCann, Managing Partner at T.Rx Capital and the former CEO of Pear Therapeutics, to unpack the promise and the pitfalls of digital therapeutics. From founding Pear to launching T.Rx Capital, Corey has focused on the intersection of biology and technology for over a decade. As a pioneer in the field, Corey shares what it took to create FDA-approved software-based treatments for addiction and insomnia, and why he believes we’re headed toward a future where digital therapeutics can become first-line care. Key Takeaways:How the U.S. behavioral health crisis affects over half the population and the ways digital therapeutics could help bridge the care gap.Greater access, standardization of best practices, and a more favorable side effect profile make digital therapeutics a compelling alternative to in-person therapy and pharmacotherapy.Despite early excitement and innovation, barriers including regulation and reimbursement have held back adoption of digital therapeutics.